Mark E Daris, an innovative inventor based in Newbury Park, California, has made significant contributions to the field of biotherapeutics. With a total of seven patents to his name, he has been instrumental in developing advanced technologies that enhance therapeutic practices.

Latest Patents

One of Daris's latest patents is focused on the LILRB1-based chimeric antigen receptor. This groundbreaking invention includes chimeric antigen receptors that feature the hinge, transmembrane region, and/or intracellular domain of LILRB1, along with functional fragments or variants. The patent also describes cells that incorporate these LILRB1-based receptors and outlines methods for their creation and application, showcasing the potential of this innovation in targeted therapies.

Career Highlights

Throughout his career, Mark E Daris has worked for prominent companies such as A2 Biotherapeutics, Inc. and Amgen Inc. His roles in these organizations have allowed him to collaborate on various pioneering projects, further establishing his reputation as a leading inventor in the biotherapeutics sector.

Collaborations

In his professional journey, Daris has collaborated with talented colleagues like Carl Alexander Kamb and Breanna Diandreth. Together, they have contributed to the development of cutting-edge solutions in biomedicine, highlighting the importance of teamwork in driving innovation.

Conclusion

Mark E Daris represents the essence of innovation in the biotherapeutics industry. His ongoing work and patent contributions continue to pave the way for advancements that have the potential to revolutionize treatments and patient care. As he forges ahead in his inventive endeavors, Daris's impact on the scientific community is undeniable.

This text is generated by artificial intelligence and may not be accurate.